Cafepharma Daily Premium (On-Demand) Archive for February, 2019

Click a link below to view the mailing archive as if it had been sent to you.

2019-02-28 23:50		CP Thu Evening Premium: FDA warns on robotic surgery for cancer
2019-02-28 13:03		CP Thu Premium: Robotic pill tests safe in humans
2019-02-27 22:10		CP Wed Evening Premium: How the FDA is addressing the opioid crisis
2019-02-27 13:16		CP Wed Premium: Judge tells BI to hand over Humira biosim launch plans
2019-02-27 00:02		CP Mon Evening Premium: An Ironwood spinoff
2019-02-26 13:47		CP Tue Premium: We live blogged the drug pricing hearing
2019-02-25 23:56		CP Mon Evening Premium: Immunomedics CEO exits after rough week
2019-02-25 13:49		CP Mon Premium: It's M&A Monday
2019-02-24 23:53		CP Sun Premium: Robots and AI
2019-02-23 17:05		CP Sat Premium: Intercept, Kayropharm, and a big Senate probe on insulin pricing
2019-02-22 14:01		CP Fri Premium: Bayer cutting 200 jobs as it restructures
2019-02-21 23:17		CP Thu Evening Premium: 130 asthma, allergy, respiratory drugs in development
2019-02-21 13:44		CP Thu Premium: Meet the seven execs slated to defend pharma on Capitol Hill
2019-02-21 00:29		CP Wed Evening Premium: Drug spending expected to accelerate
2019-02-20 13:20		CP Wed Premium: What's up next for biopharma M&A?
2019-02-19 23:54		CP Tue Evening Premium: Allergan going to split CEO-chairman roles
2019-02-19 13:32		CP Tue Premium: Pfizer's next blockbuster?
2019-02-19 00:11		CP Mon Evening Premium: Diversity at Genentech
2019-02-18 13:20		CP Mon Premium: Glenmark plans a spinoff into a US-based company
2019-02-18 00:18		CP Sun Premium: Merck and Pfizer drug extends kidney cancer survival
2019-02-16 16:40		CP Sat Premium: Big Pharma using social media influencers
2019-02-16 00:18		CP Fri Evening Premium: WHO forms committee on gene editing
2019-02-15 13:53		CP Fri Premium: Medicare might cover CAR-T
2019-02-15 00:23		CP Thu Evening Premium: Merck plans Keytruda prostate cancer studies
2019-02-14 13:39		CP Thu Premium: AstraZeneca earnings, R&D restructure, and more
2019-02-14 00:27		CP Wed Evening Premium: What will keep medtech up at night this year?
2019-02-13 13:54		CP Wed Premium: How much does a Big Pharma CEO make?
2019-02-13 00:44		CP Tue Evening Premium: Rubio outlines China's threat to US biotech
2019-02-12 13:18		CP Tue Premium: Neurogene launches to advance gene therapies for neuro disorders
2019-02-11 23:53		CP Mon Evening Premium: Love for Genentech's Xofluza Flu Treatment May Be Waning
2019-02-11 13:17		CP Mon Premium: Regeneron and Sanofi follow Amgen's lead in cutting their PCSK9 price
2019-02-10 23:16		CP Sun Premium: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
2019-02-09 14:38		CP Sat Premium: The flu vaccine prevented 8000 deaths last season
2019-02-09 00:38		CP Fri Evening Premium: JNJ's Esketamine facing FDA panel next week
2019-02-08 12:53		CP Fri Premium: Regeneron takes on Merck for heavyweight title in NSCLC
2019-02-07 23:46		CP Thu Evening Premium: How did Harpoon and Gossamer do with their IPOs?
2019-02-07 12:31		CP Thu Premium: Sanofi posts earnings beat and chops 38 R&D programs
2019-02-06 22:40		CP Wed Evening Premium: Alector's $176M Alzheimer's IPO
2019-02-06 12:00		CP Wed Premium: Takeda's hemophilia A drug + Big Pharma earnings
2019-02-05 23:44		CP Tue Evening Premium: President Trump wants drug price disclosure
2019-02-05 12:55		CP Tue Premium: Gilead drops Kite CAR-T asset, takes $820 charge
2019-02-04 23:06		CP Mon Evening Premium: Another immuno-oncology IPO
2019-02-04 13:03		CP Mon Premium: Lilly and Incyte hit the mark in ph 2 trial
2019-02-03 19:21		CP Sun Premium: Zimmer Biomet's robotics launch
2019-02-02 14:10		CP Sat Premium: What Novartis is spending "100s of millions" on
2019-02-01 22:53		CP Fri Evening Premium: Rapamycin and liver cancer
2019-02-01 13:14		CP Fri Premium: Wrapping up a week of quarterly reports
2019-02-01 00:24		CP Thu Evening Premium: Look inside the BMS-Celgene merger

<< Archive Index • Subscribe >>

Cafepharma Daily Premium (On-Demand) Archive for February, 2019

Contact Us

Past Issues

Unsubscribe